cardio.cardiac-tamponade.myxedema-effusion.v1PRODUCTION

cardio.cardiac-tamponade.myxedema-effusion.v1

Cardiac tamponade — myxedema-related pericardial effusion

cardiologyacuteadult

Hard-required inputs

0 / 10

Care setting:

Encounter flow

8/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Myxedema effusion is typically CHRONIC + MASSIVE without tamponade physiology (slow accumulation allows pericardial stretch); when tamponade present, suspect acute decompensation/concurrent pericarditis; levothyroxine + hydrocortisone are foundational; pericardiocentesis ONLY for true tamponade (Klein NEJM 2007; Wartofsky)

Inputs

Actions

Advance rule

Set

Advance when

myxedema-context effusion confirmed

Patient inputs (10)

age*demographic • CONTEXT

Older patients more vulnerable to cardiovascular ischemia from rapid levothyroxine — drives load-strategy decision per ATA 2014

echo*imaging • INITIAL_WORKUP

not present

Definitive bedside dx — characterize effusion size + tamponade physiology (often ABSENT despite massive effusion); LV wall motion + EF for hypothyroid cardiomyopathy assessment (ESC 2015; Klein NEJM 2007)

tsh_and_free_t4*lab • INITIAL_WORKUP

TSH typically >50 (often >100); free T4 markedly low (<0.5 ng/dL); confirms severe hypothyroidism etiology (ATA 2014 PMID 25266247)

cortisol_and_acth*lab • INITIAL_WORKUP

Random cortisol + ACTH BEFORE hydrocortisone empirical dose to evaluate concurrent adrenal insufficiency (5-10% concurrent in myxedema per Wartofsky); cosyntropin stimulation if borderline; pituitary disease consideration if ACTH inappropriately low

sodium*lab • INITIAL_WORKUP

Hyponatremia common in severe hypothyroidism (SIADH-like via decreased free water clearance); guides cautious fluid management — NS rather than free water; AVOID over-correction risk of osmotic demyelination (Wartofsky)

glucose*lab • INITIAL_WORKUP

Hypoglycemia common in concurrent adrenal insufficiency or severe hypothyroidism with poor intake (Wartofsky)

ecg_with_qt_assessment*imaging • INITIAL_WORKUP

not present

Low voltage + bradycardia + prolonged QT (torsades risk) define cardiac severity; QT prolongation guides electrolyte management + medication choices (Klein NEJM 2007)

sbp*vital • RED_FLAGS

Hypotension may reflect myxedema coma, concurrent adrenal insufficiency, or true tamponade — context-dependent interpretation (Wartofsky)

hr*vital • RED_FLAGS

Bradycardia (40-60 bpm) is hallmark of severe hypothyroidism — ABSENCE of compensatory tachycardia in tamponade is a key clue masking severity (Klein NEJM 2007)

temperature*vital • RED_FLAGS

Hypothermia (often <35°C) is hallmark of myxedema coma; mortality risk marker (Wartofsky)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement

informationallife_threateningmyxedema_coma_with_pericardial_effusion_overlap
Myxedema coma (altered mental status + hypothermia + bradycardia + hypoventilation) + pericardial effusion — critical care emergency with high mortality (Wartofsky)
Trigger could not be auto-evaluated — needs clinician judgement.
informationallife_threateningconcurrent_adrenal_insufficiency_in_myxedema
Concurrent autoimmune adrenal insufficiency (Schmidt syndrome / autoimmune polyglandular type 2) or pituitary disease in 5-10% of myxedema patients — risk of adrenal crisis if levothyroxine without hydrocortisone (Wartofsky; Endocrine Society 2016)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalseverelevothyroxine_induced_arrhythmia_or_ischemia
Atrial fibrillation, ventricular tachycardia, ischemic chest pain, or significant ECG changes during levothyroxine titration — over-replacement or rapid replacement in CAD patient (ATA 2014)
Trigger could not be auto-evaluated — needs clinician judgement.
informationalseverehyponatremia_worsening_with_aggressive_fluid_management
Severe hyponatremia (Na <125) worsening with overhydration or aggressive diuresis in myxedema patient — SIADH-like physiology (Wartofsky)
Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification

Loading…

Recommended regimen

Myxedema-related pericardial effusion — levothyroxine load + hydrocortisone empiric coverage + supportive care + pericardiocentesis ONLY if true tamponade (rare given chronic accumulation) (ATA 2014 PMID 25266247; Wartofsky; Klein NEJM 2007 PMID 17314344)

axis: myxedema_pericardial_effusion_thyroid_replacement_plus_adrenal_coverage_plus_selective_drainage

Selected axis "Myxedema-related pericardial effusion — levothyroxine load + hydrocortisone empiric coverage + supportive care + pericardiocentesis ONLY if true tamponade (rare given chronic accumulation) (ATA 2014 PMID 25266247; Wartofsky; Klein NEJM 2007 PMID 17314344)" by default fallback (first axis)

levothyroxine
first line
thyroid_hormone_t4
200-500 µg IV LOAD (200 elderly/CV; 500 young+healthy) → 50-100 µg IV daily • IV • load + daily
triggers: confirmed_severe_hypothyroidism_with_pericardial_effusion
Wartofsky myxedema coma protocol — IV bioavailability ~70% PO; transition to PO once tolerated; T4 → T3 conversion preferred over direct T3 in severe disease + cardiovascular caution per ATA 2014
rxcui 10582
liothyronine
add on
thyroid_hormone_t3
5-20 µg IV q8h (5 elderly/CV; 20 young+healthy) • IV • q8h × 24-48h then per response
triggers: severe_myxedema_coma_with_inadequate_t4_response_per_endocrinology
Wartofsky controversial adjunct — faster onset than T4 but higher cardiovascular toxicity risk; reserved for severe coma per endocrinology decision
rxcui 10814
hydrocortisone
first line
corticosteroid_glucocorticoid
100 mg IV q8h × 24-48h then taper if cosyntropin negative • IV • q8h
triggers: suspected_or_confirmed_concurrent_adrenal_insufficiency_or_severe_myxedema_pending_evaluation
Wartofsky — empiric coverage MUST precede full levothyroxine because increased cortisol metabolism with thyroid replacement can precipitate adrenal crisis if AI present; 5-10% concurrent AI in myxedema (Schmidt syndrome, autoimmune polyglandular)
rxcui 5492
normal saline
first line
isotonic_crystalloid
500 mL bolus then maintenance • IV • cautious bolus + maintenance
triggers: hypotension_or_dehydration_with_cautious_avoidance_of_free_water_in_hyponatremia
NS preferred over D5W in myxedema due to hyponatremia risk; avoid rapid correction (Wartofsky)
rxcui 9863
norepinephrine
rescue
vasopressor
0.05-0.1 µg/kg/min titrate to MAP ≥65 • IV • continuous
triggers: SBP_lt_85_despite_fluids_and_hydrocortisone_in_myxedema_coma
Bridge in shock physiology; consider concurrent adrenal insufficiency, true tamponade, sepsis as shock contributors (Wartofsky)
rxcui 7512
glucose 50%
rescue
concentrated_dextrose
25-50 mL D50 IV • IV • bolus per hypoglycemia
triggers: hypoglycemia_in_myxedema_with_or_without_adrenal_insufficiency
Hypoglycemia common in severe hypothyroidism + concurrent AI (Wartofsky)
rxcui 4850
magnesium sulfate
add on
electrolyte
2-4 g IV slow • IV • PRN
triggers: prolonged_QT_with_torsades_risk_in_myxedema
Bradycardia + prolonged QT in myxedema increases torsades risk; Mg replacement standard arrhythmia prophylaxis (Klein NEJM 2007)
rxcui 6585

outpatient playbook — drug actions (2)

1. continue lifelong PO levothyroxine
rxcui 10582
titrated per TSH q6-12 mo • PO • daily
trigger: Lifelong replacement
ATA 2014
2. continue hydrocortisone if AI confirmed
rxcui 5492
physiologic + stress dose education • PO • BID + stress
trigger: AI confirmed
Endocrine Society 2016

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Severe hypothyroid features (cold intolerance, weight gain, lethargy, constipation, hoarse voice, periorbital edema, dry skin, bradycardia) + dyspnea + JVD → consider myxedema effusion (Klein NEJM 2007 PMID 17314344); Echo: large pericardial effusion (often >2 cm, occasionally 1-2 L) without tamponade physiology in patient with myxedema features — chronic accumulation allows pericardial stretch (Spodick compliance curve); Known hypothyroidism off levothyroxine for months/years OR post-thyroidectomy/RAI lost to follow-up + pericardial effusion (ATA 2014 PMID 25266247).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiac tamponade — myxedema-related pericardial effusion** (cardio.cardiac-tamponade.myxedema-effusion.v1).
Scope: Myxedema effusion is typically CHRONIC + MASSIVE without tamponade physiology (slow accumulation allows pericardial stretch); when tamponade present, suspect acute decompensation/concurrent pericarditis; levothyroxine + hydrocortisone are foundational; pericardiocentesis ONLY for true tamponade (Klein NEJM 2007; Wartofsky)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Myxedema-related pericardial effusion — levothyroxine load + hydrocortisone empiric coverage + supportive care + pericardiocentesis ONLY if true tamponade (rare given chronic accumulation) (ATA 2014 PMID 25266247; Wartofsky; Klein NEJM 2007 PMID 17314344)**.
1. levothyroxine 200-500 µg IV LOAD (200 elderly/CV; 500 young+healthy) → 50-100 µg IV daily IV load + daily (thyroid_hormone_t4, first line) — Wartofsky myxedema coma protocol — IV bioavailability ~70% PO; transition to PO once tolerated; T4 → T3 conversion preferred over direct T3 in severe disease + cardiovascular caution per ATA 2014
2. liothyronine 5-20 µg IV q8h (5 elderly/CV; 20 young+healthy) IV q8h × 24-48h then per response (thyroid_hormone_t3, add on) — Wartofsky controversial adjunct — faster onset than T4 but higher cardiovascular toxicity risk; reserved for severe coma per endocrinology decision
3. hydrocortisone 100 mg IV q8h × 24-48h then taper if cosyntropin negative IV q8h (corticosteroid_glucocorticoid, first line) — Wartofsky — empiric coverage MUST precede full levothyroxine because increased cortisol metabolism with thyroid replacement can precipitate adrenal crisis if AI present; 5-10% concurrent AI in myxedema (Schmidt syndrome, autoimmune polyglandular)
4. normal saline 500 mL bolus then maintenance IV cautious bolus + maintenance (isotonic_crystalloid, first line) — NS preferred over D5W in myxedema due to hyponatremia risk; avoid rapid correction (Wartofsky)
5. norepinephrine 0.05-0.1 µg/kg/min titrate to MAP ≥65 IV continuous (vasopressor, rescue) — Bridge in shock physiology; consider concurrent adrenal insufficiency, true tamponade, sepsis as shock contributors (Wartofsky)
6. glucose 50% 25-50 mL D50 IV IV bolus per hypoglycemia (concentrated_dextrose, rescue) — Hypoglycemia common in severe hypothyroidism + concurrent AI (Wartofsky)
7. magnesium sulfate 2-4 g IV slow IV PRN (electrolyte, add on) — Bradycardia + prolonged QT in myxedema increases torsades risk; Mg replacement standard arrhythmia prophylaxis (Klein NEJM 2007)

Setting playbook (outpatient) — Long-term thyroid replacement adherence + cardiac surveillance for residual hypothyroid cardiomyopathy + monitoring effusion resolution (often months) (ATA 2014; Klein NEJM 2007)
8. continue lifelong PO levothyroxine titrated per TSH q6-12 mo PO daily — Lifelong replacement (ATA 2014)
9. continue hydrocortisone if AI confirmed physiologic + stress dose education PO BID + stress — AI confirmed (Endocrine Society 2016)

Non-pharmacologic actions:
- Endocrinology follow-up annually once stable
- Cardiology follow-up at 6 mo + 12 mo + annually × 3 yr
- Primary care for general health maintenance
- Patient + family education ongoing

AVOID / contraindication checks:
- Positive_pressure_ventilation_AVOID_pre_drain_if_true_tamponade (ESC 2015)
- Rapid_levothyroxine_titration_avoid_in_elderly_or_CAD_arrhythmia_and_ischemia_risk (ATA 2014)
- Liothyronine_t3_avoid_routine_use_cardiovascular_toxicity_only_in_severe_coma_per_endocrinology (Wartofsky controversy)
- Full_levothyroxine_BEFORE_hydrocortisone_avoid_adrenal_crisis_risk (Wartofsky)
- Free_water_d5w_avoid_in_hyponatremia_use_NS_or_3_percent_saline_if_severe (Wartofsky)
- Rapid_warming_avoid_use_passive_external_only_to_prevent_peripheral_vasodilation_collapse (Wartofsky)
- Sedatives_avoid_or_minimize_due_to_decreased_clearance_in_hypothyroidism (ATA 2014)
- Opioids_avoid_or_minimize_due_to_decreased_clearance_and_respiratory_depression (ATA 2014)
- Diuretics_avoid_aggressive_use_worsens_hyponatremia (Wartofsky)
- NSAIDs_avoid_decreased_renal_clearance_plus_GI_bleeding_risk (drug label)

Monitoring

Regimen monitoring:
- continuous ECG for arrhythmia QT bradycardia torsades during levothyroxine (Klein NEJM 2007)
- art line BP pre and post drainage if performed (Adler 2015)
- echo post intervention then per response typically serial over weeks to months for resolution
- TSH free T4 every 1-2 wk initially then q4-8 wk until stable (ATA 2014 — long half-life of T4 means slow response)
- cortisol acth results to evaluate concurrent AI (Wartofsky)
- cosyntropin stimulation test once stable to definitively assess adrenal axis (Endocrine Society)
- BMP q12 24h during acute phase for sodium and glucose (Wartofsky)
- core temperature q1h during acute phase for passive rewarming response (Wartofsky)
- ABG for CO2 retention in hypoventilation (Wartofsky)
- lactate for perfusion and sepsis screening (Wartofsky)
- cardiac function serial echo for hypothyroid cardiomyopathy recovery at 3 6 12 mo (Klein NEJM 2007)
- avoid sedation when possible to reassess neurologic status (Wartofsky)

Setting (outpatient) monitoring:
- TSH + free T4 q6-12 mo
- Echo annually × 3 yr
- Lipid + A1c per primary care

Monitoring phase: TSH + free T4 trend (response over weeks not hours); cortisol axis re-evaluation once euthyroid; effusion resolution trajectory (often months); ECG for QT + bradycardia; cardiac function recovery; AVOID over-aggressive levothyroxine titration risk of arrhythmia + ischemia (ATA 2014)

Disposition

Current setting: outpatient — Long-term thyroid replacement adherence + cardiac surveillance for residual hypothyroid cardiomyopathy + monitoring effusion resolution (often months) (ATA 2014; Klein NEJM 2007)

Disposition criteria:
- Long-term continuation under endocrinology + cardiology + primary care; cross-link to cardio.cardiac-tamponade.core.v1 for acute recurrence pathway

Escalation triggers (move to higher acuity):
- Recurrent effusion → cardiology + reconsider diagnosis (autoimmune)
- Cardiac dysfunction persisting despite euthyroid → cardiomyopathy workup
- AI crisis → emergent IV hydrocortisone + ED if AI patient
- Levothyroxine non-adherence → counseling + reinforcement

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Myxedema coma (altered mental status + hypothermia + bradycardia + hypoventilation) + pericardial effusion — critical care emergency with high mortality (Wartofsky)
- [LIFE_THREATENING] Concurrent autoimmune adrenal insufficiency (Schmidt syndrome / autoimmune polyglandular type 2) or pituitary disease in 5-10% of myxedema patients — risk of adrenal crisis if levothyroxine without hydrocortisone (Wartofsky; Endocrine Society 2016)
- [SEVERE] Atrial fibrillation, ventricular tachycardia, ischemic chest pain, or significant ECG changes during levothyroxine titration — over-replacement or rapid replacement in CAD patient (ATA 2014)

Citations

- 2014 ATA Hypothyroidism Guideline (Jonklaas Thyroid 2014 PMID 25266247) anchors levothyroxine replacement strategy + cautious approach in cardiovascular disease; Klein I, Danzi S — Thyroid Disease and the Heart (NEJM 2007 PMID 17314344) anchors hypothyroid cardiomyopathy + effusion epidemiology + ECG features; Wartofsky L — Myxedema Coma (Endocrinol Metab Clin 2006 + updates) anchors myxedema coma protocol with adrenal coverage strategy; 2015 ESC Guidelines for pericardial diseases (Adler EHJ 2015 PMID 26320112) anchors pericardial drainage + ECG/echo baseline; 2016 Endocrine Society/AACE adrenal insufficiency guideline anchors concurrent AI management with empiric hydrocortisone before cosyntropin stimulation. [PMID:26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/)
- Cited evidence (PMID 25266247) [PMID:25266247](https://pubmed.ncbi.nlm.nih.gov/25266247/)
- Cited evidence (PMID 17314344) [PMID:17314344](https://pubmed.ncbi.nlm.nih.gov/17314344/)
- Cited evidence (PMID 17456823) [PMID:17456823](https://pubmed.ncbi.nlm.nih.gov/17456823/)
- Cited evidence (PMID 20656240) [PMID:20656240](https://pubmed.ncbi.nlm.nih.gov/20656240/)

Last reconciled with current guidelines: 2026-05-15.

References

2014 ATA Hypothyroidism Guideline (Jonklaas Thyroid 2014 PMID 25266247) anchors levothyroxine replacement strategy + cautious approach in cardiovascular disease; Klein I, Danzi S — Thyroid Disease and the Heart (NEJM 2007 PMID 17314344) anchors hypothyroid cardiomyopathy + effusion epidemiology + ECG features; Wartofsky L — Myxedema Coma (Endocrinol Metab Clin 2006 + updates) anchors myxedema coma protocol with adrenal coverage strategy; 2015 ESC Guidelines for pericardial diseases (Adler EHJ 2015 PMID 26320112) anchors pericardial drainage + ECG/echo baseline; 2016 Endocrine Society/AACE adrenal insufficiency guideline anchors concurrent AI management with empiric hydrocortisone before cosyntropin stimulation. — PMID:26320112
Cited evidence (PMID 25266247) — PMID:25266247
Cited evidence (PMID 17314344) — PMID:17314344
Cited evidence (PMID 17456823) — PMID:17456823
Cited evidence (PMID 20656240) — PMID:20656240